Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 14 August 2018

Indication(s)

- Azomyr 5 mg film-coated tablets
Azomyr is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
- allergic rhinitis
- urticaria


- Azomyr 2.5 mg orodispersible tablets
Azomyr is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:
- allergic rhinitis
- urticaria


- Azomyr 5 mg orodispersible tablets
Azomyr is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
- allergic rhinitis
- urticaria


- Azomyr 0.5 mg/ml oral solution
Azomyr is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:
- allergic rhinitis
- urticaria.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000310
Orphan designation No
Date First Approved 15-01-2001
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme B.V.